ClinicalTrials.gg
CompletedNCT04141137Updated Apr 20, 2022

TRICUS STUDY Euro - Safety and Efficacy of the TricValve® Device

An interventional study of TricValve® System in Severe Tricuspid Regurgitation, sponsored by P+F Products + Features GmbH. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-20.

Sponsored by P+F Products + Features GmbH · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Tricuspid Valve Insufficiency with a site in Spain — 7 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Spain.

Started
2019
with 2 others
No phase
5 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
2 of 13
P+F Products + Features GmbH

Among the 13 studies in Tricuspid Valve Insufficiency with a site in Spain, this one is one of 3 that started in 2019, is one of 5 with no phase, and was the 4th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

7 of the 13 studies in Tricuspid Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Tricuspid Valve Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

The TricValve® Transcatheter Bicaval Valves System is indicated for relief of tricuspid insufficiency in patients with symptomatic heart disease who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy.

Read the detailed description

TricValve® Transcatheter Bicaval Valves is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients at extreme risk or who are inoperable for open surgical therapy. Pre-Clinical and Clinical preliminary studies have shown an acceptable safety and performance profile of the TricValve® Transcatheter Bicaval Valves System. Given that the medical device is a potential long-term treatment for patients with tricuspid insufficiency, clinical data for long-term treatment periods is necessary. Thus, the current study with the aim of CE certification is designed to investigate the safety and performance for at least 30 days and up to 6 months.

03

Conditions studied

  • Severe Tricuspid Regurgitation

Keywords

  • Tricuspid Valve Insufficiency
  • Heart Valve Diseases
  • Heart Diseases
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must be 18 years of age or older
  2. The subject must be a patient with severe symptomatic tricuspid regurgitation demonstrated by echocardiography with significant backflow in the lower (IVC) and/or upper (SVC) vena cava and with a v-wave ≥ 25 mmHg as demonstrated by right heart catheterization (measured in the IVC and/or SVC 2-4 cm above/ below RA inflow) within 8 weeks prior to the implantation
  3. Suitable for TricValve® Transcatheter Bicaval Valves System implantation according to anatomic criteria by computed tomography
  4. The subjects must have severe, tricuspid regurgitation leading to class III or IV
  5. The subject has ≥ 40%
  6. Distance covert in 6-minute walk test (6MWT) ≥ 60m
  7. The patient shall be screened by a "Heart Team" - including an interventional cardiologist, cardiothoracic surgeon, and agreed as a candidate for TricValve® Transcatheter Bicaval Valves System implantation
  8. Patient/authorized legal guardian understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written
  9. Patient/patient's authorized legal guardian is geographically stable (or willing to return for required study follow-up) and understands and is willing to fulfil all of the expected requirements of this clinical protocol
  10. Optimal medical treatment of patient

Exclusion criteria

Exclusion Criteria:

  1. Known significant intracardiac shunt (e.g. ventricular septal defect) or congenital structural heart disease based on heart teams decision
  2. Requirement for other elective cardiac procedures e.g. PCI (percutaneous treatment of coronary artery) or CABG (coronary artery bypass surgery) up to 90 days after the procedure or 30 days before the procedure
  3. Right ventricular failure (TAPSE ≤13mmHg)
  4. Systolic pulmonary arterial pressure > 65 mmHg as assessed by Doppler echocardiography
  5. Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's to less than one year
  6. Cerebro-vascular event within the past 3 months
  7. History of mitral/tricuspid endocarditis within the last 12 months
  8. Patient has untreated significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)
  9. Documented primary coagulopathy or disorder, including thrombocytopenia (absolute platelet count \<90k)
  10. Documented evidence of significant renal dysfunction (serum creatinine > 3.0mg/dl) or on any form of dialysis at time of screening within the last 4 weeks
  11. or known allergy to device's components, anti-coagulation therapy with vitamin K antagonists or contrast media that cannot be adequately premedicated
  12. Patients unsuitable for implantation because of thrombosis of the lower venous system or vena cava filter
  13. The patient has contraindication against a transesophageal echo (TEE) during the procedure
  14. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
  15. Liver cirrhosis Child C (see appendix)
  16. Female patient of
  17. Psychiatric or behavioural disease including known alcohol or drug abuser that is likely to impair compliance with protocol
  18. Currently participating in another study of an drug or device that would directly impact the treatment or outcome of the current study
  19. Requirement for antibiotic treatment within the last 48 hours
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    TricValve® System Single-Arm

    Two self-expanding biological valves for implantation into the inferior and superior vena cava.

    Device: TricValve® System

Interventions

  • DeviceTricValve® System

    The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with major adverse events

    The percentage of participants with major adverse events (death, myocardial infarction, cardiac tamponade, cardiac surgery for failed TricValve® implantation, stroke. Major bleeding according to Valve Academic Research Consortium (VARC) criteria)

    Time frame: 30 days

  2. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Number of Patients with improvement in quality of life as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Range of 0-100, in which higher scores reflect better health status.)

    Time frame: 3 months

Secondary outcomes

  1. Percentage of participants with major adverse events

    The percentage of participants with major adverse events

    Time frame: up to 6 months

  2. Successful implantation

    The percentage of surviving participants with successful access, delivery and retrieval of the device delivery system, and deployment and correct positioning of the intended device(s), and no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure.

    Time frame: Up to Discharge (≤ 10 days post index procedure)

  3. Unrestricted movement of cusps

    The percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography (nominal)

    Time frame: Up to 30 days, up to 6 months

  4. Cusp insufficiency

    The change of the degree of cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value

    Time frame: Up to 30 days, up to 6 months

  5. Device success

    Device success as measured by number of patients who are alive with intended device in place with no additional surgical or interventional procedures related to the TricValve®.

    Time frame: Up to 30 days, up to 6 months

  6. NYHA functional class

    Change of New York Heart Association (NYHA) functional class from III or IV to a lower one

    Time frame: Up to 30 days

  7. 6 Minute Walk Test

    Improvement in distance (m) in the 6 Minute Walk Test

    Time frame: Up to 30 days, up to 6 months

  8. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Number of Patients with improvement in quality of life as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Range of 0-100, in which higher scores reflect better health status.)

    Time frame: Up to 6 months

07

Study locations

10 sites
  • Medizinische Universität Wien
    Vienna, 1090, Austria
  • Krankenhaus Nord - Klinik Floridsdorf
    Vienna, Austria
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, Spain
  • Hospital Universitario Reina Sofia de Córdoba
    Córdoba, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
  • Hospital Clínico Universitario de Salamanca
    Salamanca, Spain
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Spain
  • Hospital Universitario Alvaro Cunqueiro
    Vigo, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2021, 16 months.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's 16 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2019
First posted
Oct 28, 2019
StartActual
Dec 9, 2019
Primary completionActual
May 5, 2021
CompletionActual
Dec 2, 2021
Last update
Apr 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04141137
Lead sponsor
P+F Products + Features GmbH
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Dec 9, 2019
Primary completion
May 5, 2021
Completion
Dec 2, 2021
Last update
Apr 20, 2022

Study contacts

Alexander Lauten, Prof.Dr.med.
principal investigator · Charite University, Berlin, Germany
Iniguez Romo Andrés, Dr.
principal investigator · Hospital Universitario Alvaro Cunqueiro- Vigo
Christian Hengstenberg, UnivProf.Dr.
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion